Company: SCYX
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001140361-25-016641
Chunk: 37

Company: SCYNEXIS INC
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 37
---
 vesting of the shares underlying such options. Vesting of all options is subject to continued service on the applicable vesting date. |

| (2) | 25% of the shares subject to this option vested on the one-year anniversary of the grant date, and 2.08% of the shares subject to the option vest on each of the next 36 months thereafter, provided the executive continues to provide continuous services to us. |

| (3) | 2.08% of the shares subject to this option vest monthly for 48 months as measured from the date of grant. |

| (4) | Year-end market price is based on the December 31, 2024 Nasdaq closing price of $1.21. |

| (5) | Represents restricted stock units that vest one third per year over three years on the anniversary of the date of grant. |

| (6) | Represents restricted stock units that vest one third per year over three years as measured from February 15, 2024. |

| (7) | Represents performance-based restricted stock units that vest upon the achievement of certain clinical development and regulatory milestones by specific dates. |

| (8) | Represents restricted stock units that vest over three years in equal, annual installments. |

Employment Agreements We have entered into an employment agreement with each of our named executive officers. These agreements generally provide for “at will” employment and set forth the terms and conditions of employment of each named executive officer. Each of the executive officers entered into a confidentiality, invention and non-competition agreement with us, which is incorporated by reference in his employment agreement. Employment agreement with Dr. Angulo . We entered into an employment agreement with Dr. Angulo in January 2023 setting forth the terms of Dr. Angulo’s employment as our Chief Executive Officer. Pursuant to the agreement, Dr. Angulo was entitled to receive an annual salary of $565,000 (which has been subsequently increased to $601,000 for 2024 and $631,050 for 2025) and is eligible to receive an annual performance bonus of up to 55% of his base salary and certain equity awards. Dr. Angulo is entitled to certain severance payments and benefits under his employment agreement, subject to executing a release and settlement agreement in a form acceptable to us, as further described below. Employment agreement with Mr. Macleod . We entered into an employment agreement with Mr. Macleod in October 2022 setting forth the